Solvemed Group
Maciej Konarowski has extensive work experience in the legal field. Maciej is currently the Head of Legal & Regulatory at SOLVEMED GROUP, a position they have held since 2020. In addition, they are the Founder of Can advocare since 2020. Prior to their current roles, they worked as a Senior Associate at KRK Kieszkowska Rutkowska Kolasiński from 2016 to 2020. Before that, they were an Advocate Trainee at DLA Piper from 2015 to 2016, where their responsibilities included advising on various areas of law, participating in litigation and dispute resolution, and providing legal services to international companies. Maciej also has previous experience as an Advocate Trainee at Bartosiak i Wspólnicy from 2011 to 2015.
Maciej Konarowski attended the University of Warsaw from 2007 to 2012, where they earned a degree in Magister prawa (Mgr prawa) in the field of Prawo. Maciej then went on to study at the District Bar Association in Warsaw from 2013 to 2016, where they obtained a degree as an Advocate. In 2018, they briefly attended the Center for American Law Studies at the University of Warsaw, although details about their degree or field of study during this time are not provided.
This person is not in any teams
This person is not in any offices
Solvemed Group
At Solvemed Group, we believe in challenging the status quo of neurological care. Our founders experienced first-hand the grave consequences of poor diagnostic standards in neurodegenerative diseases. With the primary focus in Parkinson’s disease, we leverage our proprietary machine learning technology to develop novel diagnostic-predictive digitalbiomarkers to enable first-in-class, accurate, early and cost-effective diagnostic and monitoring tools. In everything we do, we put the needs of patients and healthcare professionals first. We also happen to revolutionise drug discovery as our biomarkers enable disease-modifying drugs.We respond to the unmet needs of neurological patients by providing reliable, accurate, early diagnostics and monitoring tools for better quality care and treatment outcomes. Our work has the potential to improve healthcare systems by optimising relevant care pathways and reducing the financial burden imposed by inadequate diagnostics. Through our proprietary medical data repositories, we work with our biopharmaceutical industry partners driving clinical trial efficiency and making first-in-class disease-modifying drugs possible.Everything we do is strongly embedded in world-class science. Our global team of renowned scientists and technology experts works closely with clinical researchers from top research institutions, such as Oxford University, University College London, Harvard Medical School and Duke University, among other.